Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High-Dose Chemotherapy for Relapsed Germ Cell Tumors
NCT00231582Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2004
- Primary completion
- Jan 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin, paclitaxel, thiotepa, ifosfamide, carboplatin and 1 more in germ cell tumor (GCT), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete Response Rate. Started Sep 2004; status: completed.
02
Drugs
epirubicinpaclitaxelthiotepaifosfamidecarboplatin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00231582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231582.